Overcoming barriers to new treatment options for hepatitis C.
Brennan
Christine S
CS
Louisiana State University Health Science Center, School of Public Health, New Orleans, LA, USA.
D000998:Antiviral Agents / Q000627:therapeutic use; D000529:Complementary Therapies; D017281:Cost of Illness; D015438:Health Behavior; D006297:Health Services Accessibility / Q000458:organization & administration*; D006526:Hepatitis C / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009722:Nurse Practitioners / Q000458:organization & administration*; D009730:Nursing Assessment; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D012254:Ribavirin; D018570:Risk Assessment; D012648:Self Care; D014481:United States / Q000453:epidemiology
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin